Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to -$46.3 million.

  • Coherus Oncology's Cash from Operations rose 2527.9% to -$46.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.2 million, marking a year-over-year decrease of 4550.13%. This contributed to the annual value of -$20.4 million for FY2024, which is 8831.23% up from last year.
  • According to the latest figures from Q3 2025, Coherus Oncology's Cash from Operations is -$46.3 million, which was up 2527.9% from -$46.6 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Cash from Operations high stood at $59.7 million for Q2 2024, and its period low was -$100.0 million during Q4 2022.
  • Its 5-year average for Cash from Operations is -$31.2 million, with a median of -$46.3 million in 2025.
  • As far as peak fluctuations go, Coherus Oncology's Cash from Operations crashed by 2651542.55% in 2022, and later surged by 32113.32% in 2024.
  • Coherus Oncology's Cash from Operations (Quarter) stood at -$52.3 million in 2021, then crashed by 91.03% to -$100.0 million in 2022, then skyrocketed by 87.06% to -$12.9 million in 2023, then surged by 321.13% to $28.6 million in 2024, then crashed by 261.98% to -$46.3 million in 2025.
  • Its Cash from Operations was -$46.3 million in Q3 2025, compared to -$46.6 million in Q2 2025 and -$25.8 million in Q1 2025.